Armistice Capital LLC

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Armistice Capital LLC
CRD #168978
SEC #801-100464
CIK #0001601086
AUM 4,724.7 M (2026-03-31)
Employees 30 (63% Investors, 0% Brokers)
Fees
Minimum
Phone212-231-4930
Address510 Madison Ave
New York, NY 10022
Source [IAPD] [EDGAR] [Website] [LinkedIn]
Total AUM ($B)
6.04.83.62.41.20.02010201520212027
In the News
Mon, 22 Jun 2026 Citigroup's Upgrade Caps a Run of Bullish Calls on PTC Therapeutics, a Major Armistice Capital Holding — Daily Cal
Tue, 19 May 2026 InMed cuts preferred option exercise price from $16.60 to $0.80 in deal with Armistice Capital — Pluang
Tue, 28 Apr 2026 Jury Clears Armistice Capital, Execs Of Securities Fraud — law360.com
Wed, 15 Apr 2026 Defense says Armistice Capital trades, not fraud, drove Vaxart stock sales — Daily Journal
Tue, 14 Apr 2026 Armistice Capital Used COVID To Juice Vaxart Stock, Jury Told — law360.com
Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure]
ITEM 5 – FEES AND COMPENSATION
The fee schedules for the Funds are described in detail in each of the respective Fund’s offering
memorandum. As a general matter, Armistice (or an affiliate) is paid an annual asset-based fee (the
“Management Fee”) and, in some cases, receives performance compensation (the “Incentive Allocation”)
from the Funds.

Armistice receives a quarterly management fee calculated at an annual rate ranging from 1.25% to 1.75%
of each investor’s capital account (the “Management Fee”), depending on the series to which such investor
is subscribed (and subject to the caveat regarding waivers or modifications noted below). The Management
Fee is paid quarterly in advance, based on the value of each investor’s capital account, as of the first business
day of each calendar quarter. The Management Fee is prorated for any period that is less than a full quarter
and will be adjusted for contributions and withdrawals/redemptions made during the quarter. To the extent
Armistice receives the Management Fee at the Master Fund level, no Management Fee is paid at the Feeder
Fund level.

Subject to a loss carryforward provision, at the end of each fiscal year (December 31), the General Partner,
as the holder of certain allocation class shares of the Master Fund, receives at the Master Fund level an
annual incentive allocation ranging from 19% to 20% of the net profits (including realized and unrealized
gains and losses), if any, attributable to each investor’s capital account (the “Incentive Allocation”),
depending on the series to which such investor is subscribed. When calculating the Incentive Allocation at
the Master Fund level, net profits are reduced by the Management Fee, and all items of income, loss, and
expenses incurred at the Feeder Fund level are taken into account. The Feeder Funds may in the future
make the Incentive Allocation at the Feeder Fund level, and in such case, no Incentive Allocation will be
made at the Master Fund level.

In the event that an investor withdraws/redeems capital (in whole or in part) or retires at any time other than
at the end of a fiscal year, the deduction of the Incentive Allocation would be made with respect to such
investor as though the withdrawal/redemption was being made at the end of a fiscal year.

Under a loss carryforward provision, no Incentive Allocation will be made from the capital account of a
particular investor until any net loss previously allocated to the capital account of such investor has been
offset by subsequent net profits. Any such loss carryforward will be subject to reduction for
withdrawals/redemptions on a pro rata basis.

The General Partner/Armistice has and may continue to waive or modify the Management Fee and/or
Incentive Allocation for investors that are members, employees, or affiliates of the General Partner or
Armistice, relatives of such persons, and for certain other investors.

Armistice deducts applicable fees from each investor’s capital account. Investors do not have the ability to
choose to be billed directly for fees incurred.

The Funds pay the Management Fee; Fund legal, tax and regulatory compliance, filings and reporting
(including, without limitation, expenses attributable to regulatory filings that are made with respect to assets
of the Funds, such as Form PF, filings required to be made pursuant to Sections 13 and 16 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), and any similar non-U.S. filing obligations); fees
of third-party compliance providers; administrator, audit and accounting fees and expenses (including third-
party accounting services); fees and expenses of trading and portfolio management software; organizational
expenses; portfolio risk monitoring and risk analysis services; portfolio valuation fees and expenses
(including third-party valuation agents); fees and expenses of the establishment and ongoing operation of
any Incubator Entity (as defined in Item 10); investment expenses (whether or not the related investments
are consummated) such as commissions, research fees, and expenses (including research-related travel,

meals, and lodging, and market data and similar services); interest on margin accounts and other
indebtedness; borrowing charges on securities sold short; custodial fees; bank service fees; Fund-related
insurance costs (including D&O and E&O insurance for Armistice and the General Partner and the Master
Fund’s outside Directorship liability); the Master Fund’s Directors’ fees and expenses; fees and expenses
of the Master Fund’s AML Officers and anti-money laundering compliance; the Feeder Funds’ pro rata
share of the expenses of the Master Fund (which may include expenses of the Funds and other investment
vehicles that invest in the Master Fund); and any other expenses related to the purchase, sale or transmittal
of Fund assets. The Feeder Funds will indirectly bear the administrative and other expenses of the Master
Fund pro rata based on their interest in the Master Fund. The Offshore Fund will also pay for its shareholder
proxy voting services, its outside Directorship liability; its Board of Directors’ fees and expenses; and its
fees and expenses of AML Officers and anti-money laundering compliance. It should be noted that the
Funds bear the fees, expenses, and costs of any trade errors, except for any trade errors caused by Armistice’s
gross negligence or willful misconduct.

The Funds also pay for research with “soft” or commission dollars. Armistice has determined such research
is within the safe harbor of Section 28(e) of the Exchange Act. Refer to Item 12 – Brokerage Practices for
further information.

Certain of Armistice’s determinations with respect to whether specific expenses should be borne by
Armistice or by its Advisory Clients require subjective judgments. Armistice has a conflict of interest when
making such judgments because Armistice will bear the costs of any expenses not allocated to an Advisory
...
Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure]
ITEM 7 – TYPES OF CLIENTS
As described in Item 4, Armistice provides discretionary investment advisory services to private investment
funds.
Sector Form 13F Holdings Value ($B)
Agios Pharmaceuticals Inc 0.2
Cytokinetics Inc 0.2
PTC Therapeutics Inc 0.2
Desert Gateway Inc 0.1
Synta Pharmaceuticals Corp 0.1
Health Sciences Acquisitions Corp 0.1
Supernus Pharmaceuticals Inc 0.1
Neurocrine Biosciences Inc 0.1
Freshpet Inc 0.1
Incyte Corp 0.1
View All
Holdings by Sector ($B)
10.08.06.04.02.00.02015201920232027
Type Form D Funds Date Sold AUM
HF Armistice Capital Master Fund Ltd [2013-10-03] 704.6 M 4,724.7 M
Filed 2025-09-05 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 3 4.7
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 3 4.7
By Discretionary
Discretionary 3 4.7
Non-Discretionary 0 0.0
Total 3 4.7
By Non-United States Persons
Non-United States Persons 0.0
United States Persons 4.7
Total 3 4.7
Form D Directors Role # Filings # Firms 2011 - 2026
Steven Boyd Executive Officer 17 2
Armistice Capital LLC Executive Officer 2 2
Armistice Capital GP LLC Executive Officer 1 1
EDGAR Form CIK 2011 - 2026
13F-HR [0001601086]
3 [0001601086]
4 [0001601086]
SC 13D [0001601086]
SC 13G [0001601086]
Form 13D/13G Filer Form 13D/13G Subject Filed
Armistice Capital LLC Rigel Pharmaceuticals Inc [2026-05-15]
Armistice Capital LLC Revelation Biosciences Inc [2026-05-15]
Armistice Capital LLC Avalon Globocare Corp [2026-05-15]
Armistice Capital LLC Artelo Biosciences Inc [2026-05-15]
Armistice Capital LLC Vivos Therapeutics Inc [2026-05-15]
Armistice Capital LLC Bioxcel Therapeutics Inc [2026-05-15]
Armistice Capital LLC Calidi Biotherapeutics Inc [2026-05-15]
Armistice Capital LLC Dogwood Therapeutics Inc [2026-05-15]
Armistice Capital LLC Estrella Immunopharma Inc [2026-05-15]
Armistice Capital LLC Evogene Ltd [2026-05-15]
View All
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesHedge Fund
LEI549300KF4D500QMUP976
Form 3/4/5 Subject 2011 - 2026
Avalo Therapeutics Inc
Armistice Capital Master Fund Ltd
Boyd Steven
Armistice Capital LLC
Tenax Therapeutics Inc
Kiora Pharmaceuticals Inc
Obalon Therapeutics Inc
EnteroMedics Inc
Aytu Biopharma Inc
CTD Holdings Inc
View All
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Avalo Therapeutics Inc AVTX
Common Stock
2023-06-27 Sell 937,404 $0.52 487,450
Avalo Therapeutics Inc AVTX
Common Stock
2023-06-26 Sell 2,746,138 $0.61 1,675,144
Avalo Therapeutics Inc AVTX
Common Stock
2023-02-07 Buy 450,000
Avalo Therapeutics Inc AVTX
Warrant · derivative
2023-02-07 Buy 450,000
Avalo Therapeutics Inc AVTX
Common Stock
2023-02-03 Small acquisition 334 $3.95 1,319
Tenax Therapeutics Inc TENX
Series B Common Stock Purchase Warrants · derivative
2022-05-18 Disposed to issuer 3,175,924
Tenax Therapeutics Inc TENX
Common Stock Purchase Warrants · derivative
2022-05-18 Grant 2,072,538
Tenax Therapeutics Inc TENX
Warrant (right to buy) · derivative
2022-05-18 Grant 4,773,269
Tenax Therapeutics Inc TENX
Common Stock Purchase Warrants · derivative
2022-05-18 Grant 2,360,313
Tenax Therapeutics Inc TENX
Series C Common Stock Purchase Warrants · derivative
2022-05-18 Disposed to issuer 4,607,692
Tenax Therapeutics Inc TENX
Series B Common Stock Purchase Warrants · derivative
2022-05-18 Grant 3,175,924
Tenax Therapeutics Inc TENX
Common Stock Purchase Warrants · derivative
2022-05-18 Disposed to issuer 2,072,538
Tenax Therapeutics Inc TENX
Series C Common Stock Purchase Warrants · derivative
2022-05-18 Grant 10,596,027
Tenax Therapeutics Inc TENX
Series C Common Stock Purchase Warrants · derivative
2022-05-18 Grant 4,607,692
Tenax Therapeutics Inc TENX
Common Stock Purchase Warrants · derivative
2022-05-18 Disposed to issuer 2,360,313
Tenax Therapeutics Inc TENX
Warrant (right to buy) · derivative
2022-05-18 Disposed to issuer 4,773,269
Tenax Therapeutics Inc TENX
Pre-Funded Common Stock Purchase Warrants · derivative
2022-05-18 Grant 10,596,027
Avalo Therapeutics Inc AVTX
Common Stock
2022-03-14 Buy 100,000 $0.65 65,000
Avalo Therapeutics Inc AVTX
Common Stock
2022-03-11 Buy 100,000 $0.69 69,000
Avalo Therapeutics Inc AVTX
Common Stock
2022-03-10 Buy 26,000 $0.70 18,200
showing 20 of 200 most recent transactions
Comparable Firms State AUM
Encompass Capital Advisors LLC
NY 4,835.4 M
DME Capital Management LP
NY 4,798.9 M
Covalis Capital LLP
4,788.9 M
Covalis Gibraltar Limited
4,760.4 M
Mesarete Capital LLP
4,746.1 M
Acasta Partners US LLC
FL 4,722.4 M
Yaupon Capital Management LP
NY 4,684.2 M
Route One Investment Company LP
CA 4,681.7 M
Clean Energy Transition LLP
4,630.7 M
Summit Partners Public Asset Management LLC
MA 4,617.4 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com